focus -WSS

focus

author：hotspot 2025-10-03 00:00:06 - browse：34686

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： European officials brace for rough respiratory virus season

hotspot

WSS

Some top drug companies are starting to take action on climate

European officials brace for rough respiratory virus season

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

How housing is health care on Long Island

WATCH: Why do bright lights make us see spots?

entertainment

focus

explore

Medicare proposal to cover medical devices draws a mixed reaction

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

How one medical school became remarkably diverse

A common UTI test for kids haunts adults as a traumatic 'nightmare'

In Memoriam: Notable people who died in 2023

IVG is promising — but it won’t replace IVF quite yet

Psychedelics group wrestles with new pharma identity

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Anesthesiologist group: stop taking Ozempic before surgery

Experts study whether long Covid risk adds up with each reinfection

entertainment

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Study points to new risk in gene therapy death of Terry Horgan

Hospitals consider fixing cancer drug shortages on their own

IVG is promising — but it won’t replace IVF quite yet

Private equity could exacerbate cardiology's overuse problem, experts fear

European officials brace for rough respiratory virus season

hotspot

hotspot

focus

hotspot